| 36.66 Real-Time Quote |  -0.04 / -0.11%Today’s Change | 19.03 Today|||52-Week Range 39.00 | +58.22% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $4.5B |
Company Description
Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product ADCETRIS or brentuximab vedotin has been approved by both U.S. Food and Drug Association and Health Canada in U.S. and Canada respectively. ADCETRIS is an antibody-drug conjugate comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE). The company has four clinical-stage ADC programs, which consist of SGN-75, ASG-5ME, ASG-22ME and SGN-CD19A, as well as several preclinical product candidates, including SGN-CD33A and SGN-LIV1A. Seattle Genetics was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.
Employees
Shareholders
| Mutual fund holders | 61.01% |
| Other institutional | 46.80% |
| Individual stakeholders | 28.70% |
Top Executives
| Clay B. Siegall, PhD | Chairman, President & Chief Executive Officer |
| Eric L. Dobmeier | Chief Operating Officer & Secretary |
| Todd E. Simpson, CPA | Chief Financial Officer |
| James Kyle Bryan, MD | Vice President-Medical Affairs |
| Jorge Cerda | Vice President-Information Technology |
.
